In order to study the efficacy of both covalent and non-covalent BTK inhibitors in the context of resistant CLL cells, we created BTK variants by substituting the gatekeeper T474 residue, known to be associated with drug resistance [46, 53]. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.